Journal of Medicinal Chemistry · 2007 · 211 citations · 20 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationFragment-based Drug DesignFragment-based Lead DiscoveryFragment-based OptimizationLead DiscoveryLigand Efficiency OptimizationPotency OptimizationBeta Secretase InhibitionEnzyme Inhibition AssaysFragment OptimizationFragment-based Lead DesignFragment-based Lead OptimizationFunctional AssaysStructure-guided DesignStructure-guided Lead Discovery
Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of beta-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.
20
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sukanto Sinha, John P. Anderson, Robin Barbour et al. · Nature · 1999 · 1.6K citations
Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with Inhibitor
Hong Lin, Gerald Koelsch, Xinli Lin et al. · Science · 2000 · 706 citations